Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study-Reference-Cited by-同舟云学术

Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

Published:2020-05 Issue: Volume:131 Page:27-36
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Cortot Alexis B.,Audigier-Valette Clarisse,Molinier Olivier,Le Moulec Sylvestre,Barlesi Fabrice,Zalcman Gérard,Dumont Patrick,Pouessel Damien,Poulet Claire,Fontaine-Delaruelle Clara,Hiret Sandrine,Dixmier Adrien,Renault Patrick-Aldo,Becht Catherine,Raffy Olivier,Dayen Charles,Mazieres Julien,Pichon Eric,Langlais Alexandra,Morin Franck,Moro-Sibilot Denis,Besse Benjamin

Funder

Roche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Nivolumab versus docetaxel in advanced nonsquamousnon-small-cell lung cancer;Borghaei;N Engl J Med,2015

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentrerandomised controlled trial;Rittmeyer;Lancet,2017

4. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N Engl J Med,2018

5. Atezolizumab for first-line treatment of metastatic nonsquamousNSCLC;Socinski;N Engl J Med,2018

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to reprogram anti-inflammatory macrophages towards pro-inflammatory macrophages to support cancer immunotherapies;Immunology Letters;2024-06

2. Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer;Journal of Thoracic Disease;2024-05

3. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3;Journal of Clinical Oncology;2024-04-10

4. Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis;Translational Lung Cancer Research;2024-04

5. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer;Frontiers in Public Health;2024-02-15